KNSA - Kiniksa Pharmaceuticals, Ltd.
| Previous Close | 20.88 |
| Open | 20.95 |
| Bid | 16.40 x 800 |
| Ask | 31.50 x 1000 |
| Day's Range | 20.25 - 22.70 |
| 52 Week Range | 13.04 - 32.88 |
| Volume | 47,221 |
| Avg. Volume | 128,393 |
| Market Cap | 1.102B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.67 |
- GlobeNewswire•last month
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
-Single-doses were well-tolerated and showed reduction in pruritus-. -Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis-. HAMILTON, BERMUDA, Sept. ...
- GlobeNewswire•2 months ago
Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
HAMILTON, Bermuda, Aug. 29, 2018-- Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for ...
- GlobeNewswire•2 months ago
Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference
HAMILTON, BERMUDA, Aug. 28, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today that it will be presenting at the 2018 Wells Fargo Healthcare Conference on Thursday, September 6 th, 2018 at 8:00 a.m. ...
- GlobeNewswire•2 months ago
Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress
–Rilonacept advancing toward pivotal Phase 3 clinical trial in 2 H 2018 following recent End-of-Phase 2 communication with FDA–. –KPL-716 single-dose Phase 1 a/1b Last Subject Last Visit achieved; clinical ...
- GlobeNewswire•3 months ago
Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference
HAMILTON, Bermuda, Aug. 02, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today that it will be presenting at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14 th, 2018 at 9:45 a.m. ...
- Simply Wall St.•4 months ago
Breaking Down Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) Ownership Structure
In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...
